PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26999091-3 2016 Compounds bearing a propargylamine moiety at position 3 displayed the highest in vitro inhibitory activities against MAO-B. propargylamine 20-34 monoamine oxidase B Homo sapiens 117-122 30108930-5 2018 The compounds possessing the propargylamine moiety showed good MAO-B inhibitory activity with 6 and 8 portraying IC50 values between 14-20 fold better than ladostigil. propargylamine 29-43 monoamine oxidase B Homo sapiens 63-68 30108930-7 2018 MAO-A and MAO-B docking results showed that the propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting that the good inhibitory activity may be attributed to the propargylamine moiety and irreversible inhibition as confirmed in the reversibility studies. propargylamine 48-62 monoamine oxidase B Homo sapiens 10-15 30108930-7 2018 MAO-A and MAO-B docking results showed that the propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting that the good inhibitory activity may be attributed to the propargylamine moiety and irreversible inhibition as confirmed in the reversibility studies. propargylamine 194-208 monoamine oxidase B Homo sapiens 10-15 27396685-1 2016 Different azides and alkynes have been coupled via Cu-catalyzed 1,3-dipolar Huisgen cycloaddition to afford a novel family of N1- and C5-substituted 1,2,3-triazole derivatives that feature the propargylamine group typical of irreversible MAO-B inhibitors at the C4-side chain of the triazole ring. propargylamine 193-207 monoamine oxidase B Homo sapiens 238-243 18035186-2 2007 Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson"s disease (PD). propargylamine 64-78 monoamine oxidase B Homo sapiens 142-147 23211968-0 2013 Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity. propargylamine 45-61 monoamine oxidase B Homo sapiens 125-130 23211968-1 2013 The aim of this project was to synthesize and evaluate three novel fluorine-18 labeled derivatives of propargyl amine as potential PET radioligands to visualize monoamine oxidase B (MAO-B) activity. propargylamine 102-117 monoamine oxidase B Homo sapiens 161-180 23211968-1 2013 The aim of this project was to synthesize and evaluate three novel fluorine-18 labeled derivatives of propargyl amine as potential PET radioligands to visualize monoamine oxidase B (MAO-B) activity. propargylamine 102-117 monoamine oxidase B Homo sapiens 182-187 23908775-1 2010 Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B. propargylamine 54-68 monoamine oxidase B Homo sapiens 82-112 17017568-1 2006 Our recent studies aimed to elucidate the molecular and biochemical mechanism of actions of the novel anti-Parkinson"s drug, rasagiline, an irreversible and selective monoamine oxidase (MAO)-B inhibitor and its propargyl moiety, propargylamine. propargylamine 229-243 monoamine oxidase B Homo sapiens 167-192 18488080-3 2007 Recently, a novel selective and irreversible MAO B propargylamine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))) was approved for PD therapy. propargylamine 51-65 monoamine oxidase B Homo sapiens 45-50 16675649-2 2006 SUMMARY: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). propargylamine 48-62 monoamine oxidase B Homo sapiens 106-130 16675649-2 2006 SUMMARY: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). propargylamine 48-62 monoamine oxidase B Homo sapiens 132-137 8469735-1 1993 Specific 2-propynylamine inhibitors of monoamine oxidase (MAO) pargyline and especially chlorgyline, a selective inhibitor of MAO A (but not deprenyl, a selective inhibitor of MAO B) increase the radioprotective effect of small doses of O-methyltyramine and phenylephrine and do not change the efficacy of large doses. propargylamine 9-24 monoamine oxidase B Homo sapiens 176-181 16027398-1 2005 Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). propargylamine 40-54 monoamine oxidase B Homo sapiens 98-122 16027398-1 2005 Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). propargylamine 40-54 monoamine oxidase B Homo sapiens 124-129 14696044-3 2004 Selegiline is a selective and irreversible propargylamine type B monoamine oxidase (MAO-B) inhibitor. propargylamine 43-57 monoamine oxidase B Homo sapiens 84-89 14696044-8 2004 Recent investigations into the neuroprotective mechanism of propargylamines indicate that glyceraldehyde-3-phosphate dehydrogenase (GAPDH), MAO-B and/or other unknown proteins may represent pivotal proteins in the survival of the injured neurons. propargylamine 60-75 monoamine oxidase B Homo sapiens 140-145 7931256-5 1994 By attaching a propargylamine group the resultant series of aliphatic propargylamine derivatives have been shown to be very potent selective MAO-B inhibitors. propargylamine 15-29 monoamine oxidase B Homo sapiens 141-146 34281458-6 2021 The overall results demonstrated that substitution of the phenylethyloxy moiety at the 7-position imparted superior general activity to the derivatives, with the propargylamine substitution at the 3-position, in particular, displaying the best MAO-B selectivity and neuroprotection. propargylamine 162-176 monoamine oxidase B Homo sapiens 244-249 35447344-2 2022 Two propargylamine-containing MAO-B inhibitors, selegiline ((R)-deprenyl) and rasagiline, are currently used in the clinic for this purpose. propargylamine 4-18 monoamine oxidase B Homo sapiens 30-35